Sarcoma SACT regimens and guidelines:
Whilst every effort is made to ensure the accuracy of the information in a given regimen it cannot be guaranteed that the regimen is fully up to date, because of the dynamic nature of cancer treatment. Check the regimen details for the specific indication the regimen may be used / funded in. See our disclaimer.
Thames Valley have agreed that an H2 antagonist is no longer required as premedication before paclitaxel doses.
Therefore H2 antagonist premedication may be omitted from paclitaxel regimens.
GIST
Angiosarcoma
Chordoma
- Cisplatin Imatinib (local funding)
- Doxorubicin Cisplatin (AC) – update requires CAG approval
- Imatinib (local funding)
Ewing
- Carbplatin Etoposide
- Cyclophosphamide Topotecan
- IE/VC – update requires CAG approval
- Ifosfamide high dose – update requires CAG approval
- Irinotecan Temozolomide
- VAC
- VAI
- VDC/IE – update requires CAG approval
- VIDE
Fibromatosis
Giant cell tumours
Kaposi’s sarcoma
Osteosarcoma
- AMM (APMM) – coming soon (see 2019 regimens)
- Doxorubicin Cisplatin (AC) – update requires CAG approval
- Ifosfamide Doxorubicin
- Ifosfamide Etoposide (3 day) – coming soon
- Ifosfamide Etoposide (5 day)
- Liposomal doxorubicin
- MAP (APMM) – coming soon (see 2019 regimens)
- Mifamurtide
Rhabdomyosarcoma
- Cyclophosphamide Vinorelbine
- Irinotecan Temozolomide Vincristine (local funding)
- IVADo
- Topotecan Vincristine Doxorubicin
- VA
- VAC
- VDC/IE – update requires CAG approval
Soft tissue sarcoma
- Carboplatin Etoposide
- Cyclophosphamide prednisolone
- Dacarbazine
- Darcarbazine Gemcitabine
- Doxorubicin
- Etoposide (oral) (local funding)
- Gemcitabine Docetaxel
- Ifosfamide Doxorubicin
- Irinotecan Temozolomide
- Liposomal doxorubicin
- Trabectedin
2019 version for AMM and MAP regimens
Cisplatin hydration
SACT regimens written by S Coutts